According to the quarterly report of 2009, from January to September, the operating income reached 38.58 million yuan, an increase of 22.22% over the same period last year, and the operating profit changed from negative to positive to 400000 yuan. However, after deducting non-operating income and expenditure, the total profit is still negative. During the reporting period, corporate income tax fluctuated by 2.16 million yuan, an increase of 108% over the same period last year, and had a greater impact on net profit. During the reporting period, the net profit attributed to the parent company was-2.19 million yuan and earnings per share was-0.03 yuan.
If you lose money in successive years, you will be given a special warning of delisting risk. The company has lost money for two years in a row. according to the relevant regulations, the company's stock will implement the special treatment of delisting risk warning from April 20, 2009, that is, the stock abbreviation will be changed to "* ST national farmers".
The main business makes a profit and the sideline makes a loss. At present, the main source of income of the company is the drugs produced by Shandong Beida Hi-Tech Huatai Pharmaceutical Co., Ltd. Shandong Huatai made a net profit of 2.87 million yuan in the first half of 2009. Its main products include clindamycin phosphate and meglumine cyclic adenosine monophosphate, among which clindamycin phosphate is the most profitable, accounting for 76% of gross profit. Huayuan Pharmaceutical Network also shows that clindamycin phosphate accounts for more than 30% of the sample market. However, the company's investment in bio-pharmaceuticals is obviously insufficient. On September 23, the company gave up the capital increase and rights issue of Shandong Huatai, and the second shareholder, Shenzhen Fu Tai Investment Co., Ltd., contributed a rights issue separately. After the capital increase, the company's stake in Shandong Huatai will be diluted to 50%, while Shenzhen Fu Tailai Investment Co., Ltd. will expand from 25% to 46.43%. In addition to medicine, the company also has some real estate business, which is operated by its subsidiary Guonong Real Estate. At present, the national farmers' home purchase income mainly comes from the property management expenses of the faculty housing of China Agricultural University. The 2009 semi-annual report shows that the national farmers' home purchase loss is 2.39 million yuan. The management of the company has tried to do a real estate project, but due to lack of funds, it has not improved. Its real estate project on Chongming Island has been under construction for many years, but it is still unable to be listed for sale.
There has been no progress in the auction of major shareholders' shares. On August 18, 2008, 60% of the shares of Shenzhen Zhongnong University Science and Technology Investment Company, a major shareholder of the company, were listed for transfer on the Beijing property Exchange. As of September 18, 2009, there was still no progress on the project.
Earnings forecast and rating: out of cautious consideration, we will not give profit forecast and rating for the time being.
